Latanest

Latanoprost, the active ingredient in Latanest, is a Prostaglandin F2α analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is used in the management of glaucoma and ocular hypertension in adult patients. GNH USA supplies Latanest as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is indicated for conditions that require reduction of intra‑ocular pressure within the glaucoma disease family. Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage. Ocular hypertension: lowers intra‑ocular pressure to prevent progression to glaucoma. Secondary open‑angle glaucoma: helps control pressure when caused by other ocular conditions.

Adverse reactions may occur with ocular prostaglandin therapy.

Common Side Effects: - Eye redness or hyperemia. - Increased eyelash length and density. - Darkening of the iris or peri‑ocular skin. - Eye irritation or foreign body sensation. - Transient blurred vision.

Serious or Rare Side Effects: - Severe ocular inflammation (uveitis or iritis). - Allergic reactions such as contact dermatitis of the eyelid. - Sudden loss of vision or visual field defects. - Corneal edema or endothelial decompensation. - Persistent ocular pain or photophobia.

Before initiating therapy, clinicians should evaluate ocular health and monitor response. - Baseline intra‑ocular pressure assessment: record IOP prior to treatment. - Monitor for changes in iris color or eyelash growth: document any cosmetic alterations. - Avoid use in active ocular infection: defer until infection resolves. - Caution in patients with a history of herpetic eye disease: monitor for reactivation. - Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents that affect intra‑ocular pressure or ocular surface.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analogs: may increase risk of ocular irritation. - Combination with systemic carbonic anhydrase inhibitors: can cause excessive IOP lowering.

Moderate Interactions (Monitor Closely): - Co‑administration with beta‑blocker eye drops: monitor for additive hypotensive effect. - Use with alpha‑adrenergic agonist eye drops: observe for altered IOP response. - Topical non‑steroidal anti‑inflammatory drugs: may increase ocular surface irritation. - Systemic NSAIDs: monitor for potential changes in prostaglandin pathways.